- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04045782
Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders (SafE-OrBi)
Evaluation of the Safety and Effectiveness of Switching From Originator (Humira®) to Biosimilar (Imraldi®) Adalimumab in Flanders (SafE-OrBi)
Study Overview
Detailed Description
The physicians and IBD nurses working with IBD patients in the participating centres will be informed by the Principal Investigator (PI) with up-to-date information regarding this trial and regarding biologicals and biosimilars, with a specific emphasis on the data available for Imraldi®. The information will be given at an especially organized meeting for this purpose, which will take about two hours. Only physicians attending this meeting will be able to participate in the study.
All IBD patients with a diagnosis of CD or UC, followed by a physician who attended the meeting and who are currently on maintenance therapy with Humira® for at least 8 weeks, are eligible to be invited to enter the study. The acceptance rate will be measured at baseline as the proportion of patients who accept the switch among all patients.
In the outpatient clinic, the subject of switching from Humira® to Imraldi® can be discussed with the patient. All patients on Humira® will be informed about the possibility to switch to Imraldi® and to participate in this trial. Irrespective of their intention to switch, all patients will be offered a standardized evaluation of their current disease status, with - if necessary - adjustment of their therapy. The information is initially given by the treating physician and - if necessary - can be further fine-tuned by the IBD-nurse or physician in consecutive follow-up visits. All patients will be provided with patient information and consent form. Informed consent must be obtained prior to baseline procedures. A unique subject identification number will be assigned to each patient and used throughout the study.
From all included patients (i.e. those agreeing to switch and those declining to switch), baseline clinical characteristics (year of birth, gender, year of IBD diagnosis, previous treatment and previous surgery, smoking status, Montreal Classification, co-immunomodulatory drug use and corticoid co-administration), Humira® treatment details and visual analogue scale assessment of parameters regarding switch and overall satisfaction with current treatment, will be collected.
From the patients willing to switch, prospective data on effectiveness and safety and subjective satisfaction on different aspects of Imraldi® use, will be obtained at 3 predefined timepoints: 8 weeks, 6 and 12 months after switch to Imraldi®.
The patients who switch to Imraldi® will have blood samplings at 4 different timepoints (baseline, Week 8, Month 6 and Month 12) for analysis of ADA trough level and anti-drug antibodies, peripheral blood count (plus leucocyte differentiation) and CRP. At the same timepoints, faecal calprotectin will be measured, CDAI / Mayo clinical subscore will be assessed and patient weight recorded. A PGA will be performed, in order to get a subjective feeling of disease status/response, in order to avoid unnecessary further examinations.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Oost-Vlaanderen
-
Aalst, Oost-Vlaanderen, Belgium, 9300
- OLV Aalst
-
Gent, Oost-Vlaanderen, Belgium, 9000
- AZ Maria Middelares Gent
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (≥ 18 years of age).
- Ulcerative Colitis or Crohn's disease diagnosis.
- Maintenance therapy with Humira® for at least 8 weeks prior to switch to Imraldi®.
- Able to communicate in Flemish or French or English.
- Able and willing to voluntarily participate in the study and to provide signed informed consent.
Exclusion Criteria:
- Currently included in an interventional study.
- Pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: single arm
Adult patients (≥ 18 years of age) with Ulcerative Colitis or Crohn's Disease on maintenance therapy with Humira® for at least 8 weeks prior to switch to Imraldi®.
|
switch from originator (Humira) to biosimilar (Imraldi)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adalimumab (ADA) trough level
Time Frame: from Imraldi initiation (baseline) until month 12
|
Change from baseline in adalimumab (ADA) through level at month 12
|
from Imraldi initiation (baseline) until month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adalimumab (ADA) trough level
Time Frame: from Imraldi initiation (baseline) until month 6
|
from Imraldi initiation (baseline) until month 6
|
|
Association of adalimumab (ADA) trough level with clinical outcome (Secundary loss of Response (SLOR)
Time Frame: From Imraldi initiation (baseline) until Month 12
|
SLOR is defined as an endoscopy score of SES-CD > 3 (crohns disease) or mayo endoscopic subscore of > 1 (ulcerative Colitis)
|
From Imraldi initiation (baseline) until Month 12
|
Disease activity scores (Crohn's Disease Activity Index (CDAI) )
Time Frame: From Imraldi initiation (baseline) until Month 12
|
The CDAI score is used to quantify the symptoms of participants with Crohn's Disease.
In general, CDAI score ranges from 0 to approximately 600; higher score indicates higher disease activities.
|
From Imraldi initiation (baseline) until Month 12
|
Clinical mayo score
Time Frame: From Imraldi initiation (baseline) until Month 12
|
The clinical mayo score is used to quantify the symptoms of participants with Ulcerative colitis.
The clinical mayo score ranges from 0 to 9. The higher the score, the more severe the ulcerative colitis.
The clinical Mayo Score considers three clinical parameters, each of which is assigned a score from 0 to 3 according to the clinical evaluation.
The three clinical parameters are Stool frequency, Rectal bleeding and Physician's global assessment.
The three scores are summed to become the clinical Mayo Score.
|
From Imraldi initiation (baseline) until Month 12
|
Physician Global Assessment (PGA)
Time Frame: From Imraldi initiation (baseline) until Month 12
|
The PGA score is used to quantify the patients disease activity.
The higher the score (maximum 3 points), the more severe the ulcerative colitis.
|
From Imraldi initiation (baseline) until Month 12
|
C-Reactive protein (CRP)
Time Frame: From Imraldi initiation (baseline) until Month 12
|
Serum CRP concentrations will be measured as a marker of the degree of inflammation.
|
From Imraldi initiation (baseline) until Month 12
|
faecal calprotectin
Time Frame: From Imraldi initiation (baseline) until Month 12
|
Fecal calprotectin is a sensitive and specific marker of intestinal inflammation and response to treatment in patients with Inflammatory bowel disease.
|
From Imraldi initiation (baseline) until Month 12
|
leucocyte count
Time Frame: From Imraldi initiation (baseline) until Month 12
|
Leucocyte count is used as a marker of the degree of inflammation.
|
From Imraldi initiation (baseline) until Month 12
|
Adverse Events with a possible/probable causal relationship to adalimumab
Time Frame: From Imraldi initiation (baseline) until Month 12
|
Incidence of Adverse Events (AEs) with a possible/probable causal relationship to adalimumab
|
From Imraldi initiation (baseline) until Month 12
|
Serious Adverse Events
Time Frame: From Imraldi initiation (baseline) until Month 12
|
Incidence of Serious Adverse Events (AEs)
|
From Imraldi initiation (baseline) until Month 12
|
Patient acceptance of the switch from Humira® to Imraldi® measured by Visual Analogue Scale (VAS)
Time Frame: Single score at Baseline
|
VAS is linear and ranges from 0 to 10, with "0" representing the lowest and 10 the highest acceptance
|
Single score at Baseline
|
Patient acceptance of the switch from Humira® to Imraldi® measured by Visual Analogue Scale (VAS)
Time Frame: Single score at Week 8
|
VAS is linear and ranges from 0 to 10, with "0" representing the lowest and 10 the highest acceptance.
|
Single score at Week 8
|
Patient acceptance of the switch from Humira® to Imraldi® measured by Visual Analogue Scale (VAS)
Time Frame: Single score at Month 6
|
VAS is linear and ranges from 0 to 10 cm, with "0" representing the lowest and 10 the highest acceptance.
|
Single score at Month 6
|
Visual Analogue Scale (VAS) to measure patient satisfaction with biologic treatment
Time Frame: From Imraldi initiation (baseline) until Month 12
|
Visual Analogue Scale ranging from 0 to 10 cm, with "0" representing the lowest satisfaction and 10 the highest satisfaction.
|
From Imraldi initiation (baseline) until Month 12
|
Number of patients still treated with Imraldi®
Time Frame: at Week 8, Month 6 and Month 12
|
Persistence on Imraldi, defined as the umber of patients still treated with Imraldi.
|
at Week 8, Month 6 and Month 12
|
Number of patients who discontinued Imraldi® due to loss of effectiveness, adverse event, presence of anti-ADA antibodies or patient/physician decision.
Time Frame: From Imraldi initiation (baseline) until Month 12
|
From Imraldi initiation (baseline) until Month 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Pieter Dewint, MD, PhD, AZ Maria Middelares Gent
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SafE-OrBi
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on single arm
-
Laboratoires TheaCompleted
-
Institut du Cancer de Montpellier - Val d'AurelleFondazione IRCCS ISTITUTO NAZIONALE TUMORIWithdrawnHealthy | Non-small Cell Lung Cancer Stage III | Squamous Cell Carcinoma of Head and Neck | Metastatic Breast Cancer | Metastatic Melanoma | Advanced Renal Cell Carcinoma
-
Martin-Luther-Universität Halle-WittenbergUniversity of Leipzig; Jena University Hospital; St. Elisabeth Hospital HalleCompletedPreterm Premature Rupture of Membranes | Early Onset Neonatal Sepsis | Fetal Inflammatory Response Syndrome | Infection of Amniotic CavityGermany
-
Boston Scientific CorporationTerminated
-
University of FloridaTerminatedPain, PostoperativeUnited States
-
Philip LoizouUnknown
-
University of British ColumbiaCanadian Cancer Society (CCS)Completed
-
University of British ColumbiaCanadian Cancer Society (CCS)CompletedCancer Prevention
-
SightGlass Vision, Inc.RecruitingMyopia | Myopia Progression | Juvenile MyopiaUnited States
-
University of UtahNational Heart, Lung, and Blood Institute (NHLBI); Primary Children's HospitalRecruitingHypoxia | Neurodevelopmental Disorders | Congenital Heart Disease in Children | Complex Congenital Heart DiseaseUnited States